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We have read with interest the excellent review on sickle cell disease recently published in your 
Journal Nature Review – Disease Primers (Kato et al. 2018; 4:18019) The review succinctly 
highlights the recent advances in the molecular pathology of sickle disease, medical management 
options, and future challenges. However, the review failed to underscore the critical role of blood 
cell membrane lipid abnormality in the pathogenesis of the disease, as well as the therapeutic 
potential of long chain omega-3 fatty acids demonstrated in pilot and randomized studies [1-5].  
 
The authors have stated, "HbS polymerization directly or indirectly alters the typical lipid bilayer 
and proteins of the erythrocyte membrane”. They did not, however, mention that red and white 
blood cells and platelets of patients with SCD have an abnormal membrane fatty acid composition, 
characterized by decreased levels of docosahexaenoic (DHA, 22:6ω3) and eicosapentaenoic (EPA, 
20:5ω3) acids, and a concomitant increase in arachidonic (AA, 20:4ω6) acid [4, 6, 7]. These 
findings suggest that membrane lipid perturbation and its manifestations, including the exposure 
of phosphatidyl serine on the exterior of red blood cell membranes and the propensity of 
erythrocytes, white blood cells, and platelets to adhere and aggregate is fundamental to sickle cell 
pathology.  
 
Tomer et al [1], reported a lower frequency of pain episodes in SCD patients treated with omega-
3 fatty acids. Subsequent to the aforementioned pilot study, Daak et al [5] conducted a large single 
center randomized, double-blind, placebo-controlled trial with omega-3 fatty acids in patients with 
homozygous sickle cell disease. The annual vaso-occlusive crisis rate (VOC), number of 
hospitalization days for VOC, and rate of hospitalizations were significantly lower in the omega-
3 group than in subjects who received placebo capsules. We have recently concluded a multi-
center (n=11) phase 2 randomized, double-blind, placebo-controlled, parallel-group, dose-finding 
trial (SCOT) in the United States. Our preliminary data, consistent with previous findings, reveals 
a greater than 55% reduction in clinical sickle cell crises in patients treated with DHA. A detailed 
protocol of the SCOT trial is provided on the ClinicalTrials.gov website 
(https://clinicaltrials.gov/ct2/show/NCT02973360).   
These clinical studies provide evidence that omega-3 fatty acids are effective and safe treatment 
options for patients with sickle cell disease. The specific mechanisms through which these fatty 
acids ameliorate vaso-occlusive crises is yet to be elucidated. Nevertheless, omega-3 fatty acids 
and their active metabolites have well-substantiated pleiotropic biological actions - anti-
inflammatory, inflammation resolving, anti-adhesion, anti-aggregation, vasodilatory and 
antioxidant [8-11]. In addition, there is evidence that membrane fatty acid abnormality, red blood 
rheological abnormalities, inflammation and hemolysis are ameliorated by treatment with DHA 
and EPA[11-14].    
In the last 20 years, only one drug has been approved for SCD and most of the experimental 
medications have failed to live up to their earlier promise. This is to be expected because of the 
complex nature of SCD pathophysiology. Hence, multimodal therapy or a single drug with 
multiple mechanisms of action may be necessary to achieve clinical effectiveness[15, 16]. The 
multipronged biological and pleiotropic effects of omega-3 fatty acids make them a novel 
therapeutic option for patients with SCD.  
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